Actavis launches generic drug for prostate cancer

Bicalutamide from Acatvis pharmaceuticals is the first generic version of the prostate cancer drug to be made available in the UK, France and Germany.
Actavis, the international generic pharmaceuticals company, has launched Bicalutamide tablets in the UK, France and Germany.
Bicalutamide, the generic version of AstraZeneca’s Casodex, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK.

Bicalutamide Actavis was launched as soon as the brand product’s patent expired; on 8th July in the UK and 9th July in Germany and France. Distribution of the product began immediately.

Svend Andersen, Actavis Executive Vice President of Western Europe Sales, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market - creating value for patients at a lower price. Bicalutamide....is used in treating prostate cancer and also in combination with other treatments of malign diseases, prescribed by both hospitals and general practitioners.”

Actavis was able to launch generic Bicalutamide in some of its countries of operation as early as 2007, including the Czech Republic, Slovakia, Poland and Iceland.

Actavis is one of the world’s leading generic drug companies specialising in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 40 countries and 11,000 employees.

More information on Actavis and generic drugs can be found on the corporate website: www.actavis.com

Contact Information

Hjordis Arnadottir

Director, External Communications

Actavis

Contact via E-mail